Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fordyce says he has no MBA but knows business is people and money. He states plainly that 'no cash, no company,' and because biotech mostly raises through equity, CEOs must be disciplined about stock price and financing. He sees that as a core CEO job alongside organizing people and time around translation.

Related Insights

David Solomon's career from academia to VC to CEO highlights a key formula for biotech leadership: combining a disciplined, scientific approach with savvy corporate finance to effectively translate good science into innovative medicines for patients.

Beyond funding operations, a strong cash position is a crucial, often unstated, strategic asset for biotechs. It provides significant leverage in partnership discussions with large pharmaceutical companies, allowing smaller firms to reject unfavorable terms and signal they do not need a deal to survive.

Even with strong scientific data, biotech companies struggle for funding because investor capital chases short-term fads like AI. The belief that "good science will attract money" is a utopian myth; leaders must actively navigate fickle market psychology to survive and raise capital.

Alan Bash's biggest learning after moving from Bristol-Myers Squibb to smaller biotechs was the constant pressure of cash runway. Unlike in large pharma where budgets are a concern, in biotech, cash availability dictates all strategic choices, including partnerships and M&A.

Voyager CEO Al Sandrock, a physician-scientist, found his biggest challenge wasn't R&D but the business side. For pre-revenue biotechs, managing cash runway is the primary survival skill, requiring new CEOs to quickly learn finance from mentors and board members.

Beyond scientific knowledge, the most effective biotech CEOs possess a specific set of traits. They must be decisive, maintain ruthless capital discipline (even for small amounts), and consistently demonstrate strategic clarity, especially when facing the immense pressure inherent in the industry.

CellSci CEO Gerd Kirsten, a lawyer and financier, argues his primary function is protecting the company from market manipulation. He contends that his law and finance background has been more critical for survival than scientific expertise, which is useless without funding.

Despite having a cash runway through the end of its pivotal study, Complement's CEO emphasizes that a leader is 'never not raising money.' This approach allows the company to operate from a position of strength, focusing on execution while opportunistically checking the market temperature and planning for the next phase without financial pressure.

CEO Ron Cooper likens a biotech startup to a fire needing three elements in sync: science (the log), people (the spark), and money (oxygen). An imbalance, such as science outpacing funding, will destroy value by forcing compromised decisions.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.